JP2003004741A - Method for judging antigen-antibody reaction - Google Patents
Method for judging antigen-antibody reactionInfo
- Publication number
- JP2003004741A JP2003004741A JP2001181922A JP2001181922A JP2003004741A JP 2003004741 A JP2003004741 A JP 2003004741A JP 2001181922 A JP2001181922 A JP 2001181922A JP 2001181922 A JP2001181922 A JP 2001181922A JP 2003004741 A JP2003004741 A JP 2003004741A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- measurement
- reaction
- antibody
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 56
- 238000005259 measurement Methods 0.000 claims abstract description 50
- 102000036639 antigens Human genes 0.000 claims abstract description 38
- 108091007433 antigens Proteins 0.000 claims abstract description 38
- 239000000427 antigen Substances 0.000 claims abstract description 37
- 239000007853 buffer solution Substances 0.000 claims abstract description 10
- 239000000725 suspension Substances 0.000 claims abstract description 9
- 239000000872 buffer Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 abstract description 8
- 230000004520 agglutination Effects 0.000 abstract description 6
- 230000001900 immune effect Effects 0.000 abstract description 4
- 238000000691 measurement method Methods 0.000 abstract description 4
- 206010029719 Nonspecific reaction Diseases 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 238000006386 neutralization reaction Methods 0.000 description 27
- 238000012360 testing method Methods 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 15
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000004816 latex Substances 0.000 description 8
- 229920000126 latex Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
【発明の詳細な説明】
【0001】
【発明の属する技術分野】本発明は、免疫学的測定の分
野に属し、詳しくは抗原抗体反応を利用した測定に関
し、その測定結果の簡便かつ精度の高い判定方法に関す
る。
【0002】
【従来の技術】抗原抗体反応は、微量成分の検出のため
に、日常的に利用されている。免疫学的測定方法におい
ては、測定された結果が抗原抗体反応によるかどうかを
判定することが重要な意味を有する。例えば、特開平0
2−80956号公報には、スライド上等の基体表面上
にて、凝集反応試薬と混合し、抗原−抗体反応の結果生
じる凝集像を観察し、判定し、その後、pHを3.0以
下、若しくは9.0以上に変化させ、またイオン濃度を
0.5M以上とし、高濃度のカオトオロピックイオンを
含む化学物質を添加して、凝集が乖離するかどうかで、
非特異凝集かどうかを確認する方法が開示されている。
【0003】また、特表平11−511255号公報に
は、IgM抗体に特異的な結合構成員を固定した固定材
料を含む試薬を形成し、固相材料に結合してIgM抗体
からIgG抗体から乖離を起こすのに充分低いpHとす
ることにより、判定する方法が開示されている。
【0004】免疫反応を用いる方法は、特異的な抗原−
抗体反応を利用するため、測定特異性の高い方法であ
る。しかし、検体の状態等により、非特異的凝集反応を
起こす場合があり、測定結果に誤差を生じる場合があ
る。
【0005】このような問題を解決するため、抗原抗体
反応か非特異的凝集反応かを確認する手段として、上記
の例では、起こった反応が抗原抗体反応であった場合の
抗原抗体反応の乖離条件(pHの変化、イオン強度、カ
オトロピックイオンの変化等)により、判定している
が、このような方法においては、抗原抗体反応以外の非
特異的な反応の場合も乖離が起こる場合があり、抗原抗
体反応かどうかを判定できないことがある。
【0006】
【発明が解決しようとする課題】上記現状に鑑み、本発
明は、非特異的凝集反応が起こったか否かにかかわら
ず、正確な測定結果を得ることができる免疫学的測定方
法を確立することができる判定方法を提供することを目
的とする。
【0007】
【課題を解決するための手段】本発明は、抗原又は抗体
を担持した不溶性担体を用いて、担持された抗原又は抗
体に対応する抗体又は抗原を測定する抗原抗体反応の判
定方法であって、前記測定のための試薬構成は、不溶性
担体の懸濁液及び緩衝液からなる2液以上の試薬を用
い、測定時にはこれらの試薬が混合されるものであり、
前記測定は2度行うものであり、第1回目の検体測定時
に反応が起こった検体に対して、試薬構成中の測定に供
する緩衝液を、不溶性担体に担持したものと同じ抗体又
は抗原を含む緩衝液と入れ換えたのちに第2回目の測定
をし、最初の反応に対する、前記緩衝液での反応の減少
度合を測定することにより特異的反応であるか非特異的
反応であるかを判定する抗原抗体反応の判定方法であ
る。以下に本発明を詳述する。
【0008】本発明においては、不溶性担体の懸濁液、
緩衝液からなる通常測定試薬構成の緩衝液と、予め不溶
性担体に担持した抗体又は抗原と同様の特異性をもつ抗
体又は抗原を含む緩衝液(以下、「中和緩衝液」とい
う)とを取り替え、再測定することにより、検体中の抗
原又は抗体を消費させながら再び測定する。このような
手段を取ることにより、検体を別容器に移し変えたりす
る手間なく、抗原・抗体が消費されたかどうかを調べる
ことができ、特異性を保ったまま、非常に簡便に抗原抗
体反応の確認を行うことができる。
【0009】不溶性担体に吸着又は結合する、また、中
和緩衝液に含有される抗原としては、蛋白質抗原、脂質
抗原、ハプテン、ハプテンをキャリア(たとえばBSA
のような蛋白質)に結合させたもの等、免疫測定法に用
いることが可能であれば、その性状は問わない。また、
精製蛋白質等の場合、不溶性担体に吸着又は結合するも
のと同様の特異性をもつものであれば、動物種、組織等
が同一由来である必要はない。
【0010】不溶性担体に吸着又は結合する、また、中
和緩衝液に含有される抗原としては、ポリクローナル抗
体、モノクローナル抗体のいずれもが用いることが可能
であり、また、その酵素消化断片を使用することもでき
る。また、不溶性担体に吸着、結合する抗体が必ずしも
同一の種由来の抗体である必要はなく、また、一方がモ
ノクローナル抗体で、もう一方がポリクローナル抗体で
あってもかまわない。
【0011】測定系は、ラテックス懸濁液、緩衝液等か
らなる構成であれば、液数を問わない。すなわち、緩衝
液を2種類以上、ラテックス懸濁液を2種類以上に分割
した試薬構成でも差し支えない。また、測定時に最低ラ
テックス懸濁液1種と緩衝液1種の計2種類以上であれ
ば、保存時に緩衝液を2種類以上、ラテックス懸濁液を
2種類以上の複数に分割しておく保存方法も本発明を妨
げるわけではない。
【0012】中和率も数値に限定はない。判定を容易に
するためには、判定基準として中和率を50%以上の高
値とできるほうが好ましいが、力価の高い抗体、精製度
の高い抗原等が手に入りにくい場合においても、中和の
有無が判別できれば本発明を妨げるものではない。
【0013】
【実施例】以下に、本発明の実施例及び比較例を挙げる
ことにより、本発明をさらに詳細に述べる。本発明は以
下の実施例に限定されるものではない。
(実施例1) HBs抗原測定試薬への適用−1
1)第1試薬(緩衝液)の調製
(1)通常測定用第1試薬の調製
ウシ血清アルブミン(以下、BSAともいう)を1重量
%含有するリン酸−食塩緩衝液(0.05M リン酸緩
衝液(pH7.0)、0.1M NaCl、以下、0.
05MPBSともいう)に、平均分子量50万のポリエ
チレングリコール(和光純薬工業社製、以下、PEGと
もいう)を1.0重量%の濃度になるように溶解した。
上記溶液1Lに対し、更に、正常ウサギ血清を3.0μ
L添加し、通常測定用第1試薬を調製した。
(2)中和用第1試薬の調製
BSAを1重量%含有する0.05MPBSに、PEG
を1.0重量%の濃度になるように溶解した。上記溶液
1Lに対し、更に、抗HBs抗血清(ウサギ)(特異抗
体力価8000IU/mL(メディエースHBs抗体
(積水化学工業社製)にて測定)を3.0μL添加し、
中和用第1試薬を調製した。
【0014】2)第2試薬(抗HBs抗体感作ラテック
ス液)の調製
抗HBsウサギ抗体(精製品)を1.0mg/mLの濃
度で含む、リン酸−食塩緩衝液(0.036M リン酸
緩衝液(pH6.6)、0.1M NaCl、以下、0.
036MPBSともいう)1.25mLに、平均粒径
0.3μmのポリスチレンラテックス(固形分10%
(W/V)、積水化学工業社製)1mLと0.036M
PBSとを添加し、30℃にて60分間攪拌した。次い
で、この液にBSAを1重量%含有する0.05MPB
Sを添加し、30℃にて60分間攪拌した後、4℃にて
20分間、18000rpmで遠心分離することにより
洗浄した。洗浄操作は3回行った。得られた沈殿物にB
SAを1重量%含有する0.05MPBS100mLを
添加し、ラテックスを懸濁した後、超音波破砕機にて分
散処理を行い、固形分0.1%(W/V)の抗HBs抗
体感作ラテックス液を調製した。これを第2試薬とし
た。
【0015】3)HBs抗原測定試薬
HBs抗原測定試薬としては、通常測定、即ち、HBs
抗原の測定の際には、通常測定用第1試薬と第2試薬と
を用いた。また、中和試験、即ち、HBs抗原の確認試
験の際には、中和用第1試薬と第2試薬とを用いた。
【0016】4)標準HBs抗原液、中和試験用検体
標準品としてHBs抗原を0、50、100、300、
500IU/mL濃度で含むヒト血清を使用した。ま
た、検体として、HBs抗原陽性血清:A〜E、及び、
偽陽性血清F〜Jを使用した。ここで偽陽性血清とは、
健常人から採取された血清であるが、通常試験にて陽性
と判定されたものである。
【0017】5)通常測定方法
(1)検量線の作成
検体20μLと通常測定用第1試薬150μLとを混合
し、37℃で適時保存した後、第2試薬150μLを添
加攪拌した。この後、1分後及び5分後の波長750m
mでの吸光度を測定し、この差を吸光度変化量(ΔAb
s)とした。測定には日立7150形自動分析装置を使
用した。予め、標準品について測定を行って検量線を作
成しておき、以下の測定では検体の吸光度変化量を上記
検量線に代入して、検体中のHBs抗原量を算出した。
【0018】(2)検体の測定
HBs抗原陽性血清及び偽陽性血清を検体として、上記
5)−(1)の測定方法に従って、HBs抗原量を測定
した。結果を表1に示した。
【0019】6)中和試験方法
上記5)−(2)の通常測定で陽性と判定された検体に
ついて中和試験を実施した。HBs抗原陽性血清及び偽
陽性血清を検体として、通常測定用第1試薬を中和用第
1試薬に交換した以外は上記5)−(1)と同様に、測
定を実施した。結果を表1に示した。また、表中の中和
率は、下記式に従い算出した。
【0020】
【数1】
【0021】7)結果の判定
結果の判定は以下の基準に従った。
(1)通常測定
・測定値が8IU/mL未満・・・陰性
・測定値が8IU/mL以上・・・陽性
(2)中和試験
・中和率が50%未満・・・陰性
・中和率が50%以上・・・陽性
【0022】(実施例2) HBs抗原測定試薬への適
用−2
実施例1の通常測定用第1試薬及び中和用第1試薬の調
製を以下のように行った以外は、実施例1と同様に行っ
た。結果を表1に示した。
1)第1試薬(緩衝液)の調製
(1)通常測定用第1試薬の調製
BSAを1重量%含有する0.05MPBSに、PEG
を1.0重量%の濃度になるように溶解した。上記溶液
1Lに対し、更に、0.036MPBSを8.0μL添
加し、通常測定用第1試薬を調製した。
(2)中和用第1試薬の調製
BSAを1重量%含有する0.05MPBSに、PEG
を1.0重量%の濃度になるように溶解した。上記溶液
1Lに対し、更に、抗HBsウサギ抗体(精製品、緩衝
液:0.036MPBS)(蛋白濃度:1.0mg/m
L、特異抗体力価:5300IU/mL(メディエース
HBs抗体(積水化学工業社製)にて測定)を8.0μ
L添加し、中和用第1試薬を調製した。
【0023】
【表1】
【0024】(比較例1)通常測定用第1試薬の調製を
以下のように行い、また、実施例1の中和用第1試薬に
代えて下記1)−(2)の確認試験用第1試薬を用いて
試験を実施した以外は、実施例1と同様に行った。結果
を表2に示した。
【0025】1)第1試薬(緩衝液)の調製
(1)通常測定用第1試薬の調製
BSAを1重量%含有する0.05MPBSに、PEG
を1.0重量%の濃度になるように溶解し、通常測定用
第1試薬を調製した。
(2)確認試験用第1試薬の調製
BSAを1重量%含有するホウ酸Na−HCl緩衝液
(pH9.15)に、PEGを1.0重量%の濃度にな
るように溶解し、確認試験用第1試薬を調製した。
【0026】(比較例2)通常測定用第1試薬の調製を
以下のように行い、また、実施例1の中和用第1試薬に
代えて下記1)−(2)の確認試験用第1試薬を用いて
試験を実施した以外は、実施例1と同様に行った。結果
を表2に示した。
【0027】1)第1試薬(緩衝液)の調製
(1)通常測定用第1試薬の調製
BSAを1重量%含有する0.05MPBSに、PEG
を1.0重量%の濃度になるように溶解し、通常測定用
第1試薬を調製した。
(2)確認試験用第1試薬の調製
BSAを1重量%含有するホウ酸Na−HCl緩衝液
(pH9.15)に、NaClを0.5Mの濃度になる
ように、またPEGを1.0重量%の濃度になるように
溶解し、確認試験用第1試薬を調製した。
【0028】
【表2】【0029】実施例1及び2においては、HBs抗原陽
性血清について5検体とも通常試験では8IU/mL以
上を示し、中和率も50%を超えたため、陽性と判定さ
れた。一方、偽陽性血清については5検体とも通常試験
では8IU/mLを超えたが、中和率が50%未満であ
るため、陰性と判定された。比較例1及び2において
は、HBs抗原陽性血清について5検体とも通常試験で
8IU/mL以上を示し、中和率も50%を超えたた
め、陽性と判定された。しかし、偽陽性血清については
5検体とも通常試験では8IU/mLを超え、更に5検
体中4検体は中和率も50%以上になったため、陽性と
判定されてしまった。
【0030】
【発明の効果】本発明は上述の構成よりなるので、検体
を別容器に移しかえたりする手間なく、抗原及び/又は
抗体が消費されたかどうかを調べることができ、非常に
簡便に抗原抗体反応の中和試験を行うことができる。Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention belongs to the field of immunological measurement, and more particularly to a measurement utilizing an antigen-antibody reaction, and the measurement results are simple and highly accurate. It relates to a judgment method. [0002] An antigen-antibody reaction is routinely used for detecting a trace component. In an immunological measurement method, it is important to determine whether the measured result is due to an antigen-antibody reaction. For example, JP
No. 2-80956 discloses that on a substrate surface such as a slide, an agglutination reagent is mixed, an agglutination image resulting from an antigen-antibody reaction is observed and determined, and then the pH is adjusted to 3.0 or less. Alternatively, the concentration is changed to 9.0 or more, and the ion concentration is set to 0.5M or more, and a chemical substance containing a high concentration of chaotropic ions is added to determine whether or not aggregation is dissociated.
A method for confirming non-specific aggregation is disclosed. [0003] Also, Japanese Patent Application Laid-Open No. 11-511255 discloses that a reagent containing an immobilizing material in which a specific binding member specific to an IgM antibody is immobilized, bound to a solid phase material, and then converted from an IgM antibody to an IgG antibody. A method is disclosed in which the pH is determined to be sufficiently low to cause a divergence. [0004] A method using an immune reaction is a method for specific antigen-
Since the antibody reaction is used, the method has high measurement specificity. However, a non-specific agglutination reaction may occur depending on the state of the sample, and an error may occur in the measurement result. [0005] In order to solve such a problem, as a means for confirming whether an antigen-antibody reaction or a non-specific agglutination reaction occurs, in the above-described example, the deviation of the antigen-antibody reaction when the reaction occurred is an antigen-antibody reaction. Judgment is made based on conditions (change in pH, ionic strength, change in chaotropic ion, etc.), but in such a method, dissociation may occur even in non-specific reactions other than antigen-antibody reaction, It may not be possible to determine whether it is an antigen-antibody reaction. [0006] In view of the above situation, the present invention provides an immunological measurement method capable of obtaining an accurate measurement result regardless of whether a non-specific agglutination reaction has occurred. It is an object to provide a determination method that can be established. [0007] The present invention provides a method for determining an antigen-antibody reaction in which an insoluble carrier carrying an antigen or an antibody is used to measure an antibody or an antigen corresponding to the carried antigen or the antibody. The reagent configuration for the measurement uses two or more reagents consisting of a suspension of an insoluble carrier and a buffer, and these reagents are mixed at the time of measurement.
The measurement is performed twice, and for the sample that has undergone a reaction at the time of the first sample measurement, the buffer to be used for measurement in the reagent composition contains the same antibody or antigen as that supported on the insoluble carrier. After replacing the buffer, the second measurement is performed, and the degree of decrease in the reaction with the buffer relative to the first reaction is measured to determine whether the reaction is a specific reaction or a non-specific reaction. This is a method for determining an antigen-antibody reaction. Hereinafter, the present invention will be described in detail. In the present invention, a suspension of an insoluble carrier,
Replace the buffer consisting of a normal measurement reagent consisting of a buffer with a buffer containing an antibody or antigen having the same specificity as the antibody or antigen previously carried on an insoluble carrier (hereinafter referred to as "neutralization buffer"). The measurement is performed again while consuming the antigen or antibody in the sample. By taking such a measure, it is possible to check whether the antigen / antibody has been consumed without having to transfer the sample to another container, and it is very easy to carry out the antigen-antibody reaction while maintaining the specificity. Confirmation can be performed. As antigens adsorbed or bound to an insoluble carrier and contained in the neutralization buffer, protein antigens, lipid antigens, haptens, and haptens include carriers (eg, BSA).
The properties thereof are not limited as long as they can be used in immunoassays, such as those bound to proteins such as Also,
In the case of a purified protein or the like, animal species, tissues and the like need not be of the same origin as long as they have the same specificity as those adsorbed or bound to an insoluble carrier. As the antigen to be adsorbed or bound to the insoluble carrier and contained in the neutralization buffer, either a polyclonal antibody or a monoclonal antibody can be used, and an enzyme-digested fragment thereof is used. You can also. Further, the antibodies adsorbing and binding to the insoluble carrier need not necessarily be antibodies of the same species, and one may be a monoclonal antibody and the other may be a polyclonal antibody. The measuring system is not limited as long as it is composed of a latex suspension, a buffer or the like. That is, a reagent configuration in which the buffer solution is divided into two or more types and the latex suspension is divided into two or more types may be used. If at least two types of latex suspension and one type of buffer are used at the time of measurement, two or more types of buffer and two or more types of latex suspension are stored during storage. The method does not hinder the present invention. The neutralization rate is not limited to a numerical value. In order to facilitate the determination, it is preferable that the neutralization ratio can be set to a high value of 50% or more as a criterion. However, even when it is difficult to obtain high titer antibodies, highly purified antigens, etc. The present invention is not hampered as long as the presence or absence can be determined. The present invention will be described below in more detail by giving Examples and Comparative Examples of the present invention. The present invention is not limited to the following examples. (Example 1) Application to HBs antigen measurement reagent-1 1) Preparation of first reagent (buffer) (1) Preparation of first reagent for normal measurement 1% by weight of bovine serum albumin (hereinafter also referred to as BSA) Phosphate-salt buffer solution (0.05 M phosphate buffer (pH 7.0), 0.1 M NaCl;
Polyethylene glycol having an average molecular weight of 500,000 (manufactured by Wako Pure Chemical Industries, Ltd .; hereinafter, also referred to as PEG) was dissolved at a concentration of 1.0% by weight in 05 MPBS.
To 1 L of the above solution, 3.0 μl of normal rabbit serum was further added.
L was added to prepare a first reagent for normal measurement. (2) Preparation of first reagent for neutralization PEG was added to 0.05M PBS containing 1% by weight of BSA.
Was dissolved to a concentration of 1.0% by weight. To 1 L of the above solution, 3.0 μL of an anti-HBs antiserum (rabbit) (specific antibody titer: 8000 IU / mL (measured with a media Ace HBs antibody (manufactured by Sekisui Chemical Co., Ltd.)) was added.
A first reagent for neutralization was prepared. 2) Preparation of second reagent (anti-HBs antibody-sensitized latex solution) Phosphate-salt buffer (0.036 M phosphate) containing anti-HBs rabbit antibody (purified product) at a concentration of 1.0 mg / mL Buffer solution (pH 6.6), 0.1 M NaCl;
036 MPBS) in 1.25 mL of polystyrene latex having an average particle size of 0.3 μm (solid content: 10%
(W / V), manufactured by Sekisui Chemical Co., Ltd.) 1 mL and 0.036M
PBS and the mixture were stirred at 30 ° C. for 60 minutes. Next, 0.05MPB containing 1% by weight of BSA in this solution.
After adding S, the mixture was stirred at 30 ° C. for 60 minutes, and then washed by centrifugation at 4 ° C. for 20 minutes at 18,000 rpm. The washing operation was performed three times. B in the resulting precipitate
100 mL of 0.05M PBS containing 1% by weight of SA was added thereto, and the latex was suspended. The suspension was subjected to dispersion treatment using an ultrasonic crusher to give an anti-HBs antibody-sensitized latex having a solid content of 0.1% (W / V). A liquid was prepared. This was used as the second reagent. 3) Reagent for measuring HBs antigen The reagent for measuring HBs antigen is usually measured, that is, HBs antigen.
In the measurement of the antigen, the first and second reagents for measurement were usually used. In the neutralization test, that is, in the test for confirming the HBs antigen, the first and second reagents for neutralization were used. 4) Standard HBs antigen solution, 0, 50, 100, 300, HBs antigen as a sample standard for neutralization test
Human serum at a concentration of 500 IU / mL was used. As samples, HBs antigen-positive sera: A to E, and
False positive sera FJ were used. Here, false positive serum is
Serum collected from a healthy person, which was determined to be positive in a normal test. 5) Normal measurement method (1) Preparation of calibration curve 20 μL of the sample and 150 μL of the first reagent for normal measurement were mixed and stored at 37 ° C. as appropriate, and 150 μL of the second reagent was added and stirred. After this, the wavelength 750m after 1 minute and 5 minutes
m, and the difference is determined by the change in absorbance (ΔAb).
s). A Hitachi 7150 type automatic analyzer was used for the measurement. A standard curve was prepared in advance by measuring the standard product, and in the following measurement, the amount of HBs antigen in the sample was calculated by substituting the change in absorbance of the sample into the above-mentioned calibration curve. (2) Measurement of Sample The amount of HBs antigen was measured using the HBs antigen positive serum and the false positive serum as samples according to the above-mentioned method 5) to (1). The results are shown in Table 1. 6) Neutralization test method A neutralization test was carried out on a sample which was determined to be positive in the normal measurement of the above 5)-(2). The measurement was performed in the same manner as in 5)-(1) above, except that the HBs antigen-positive serum and the false-positive serum were used as samples, and the first reagent for normal measurement was replaced with the first reagent for neutralization. The results are shown in Table 1. The neutralization ratio in the table was calculated according to the following equation. ## EQU1 ## 7) Judgment of results Judgment of the results was made according to the following criteria. (1) Normal measurement / measured value is less than 8 IU / mL ... negative / measured value is 8 IU / mL or more ... positive (2) Neutralization test / neutralization rate is less than 50% ... negative / neutralization (Example 2) Application to HBs antigen measurement reagent-2 Preparation of the first reagent for normal measurement and the first reagent for neutralization in Example 1 is as follows. Except having performed, it carried out similarly to Example 1. The results are shown in Table 1. 1) Preparation of first reagent (buffer solution) (1) Preparation of first reagent for normal measurement PEG was added to 0.05 M PBS containing 1% by weight of BSA.
Was dissolved to a concentration of 1.0% by weight. To 1 L of the above solution, 8.0 μL of 0.036 MPBS was further added to prepare a first reagent for normal measurement. (2) Preparation of first reagent for neutralization PEG was added to 0.05M PBS containing 1% by weight of BSA.
Was dissolved to a concentration of 1.0% by weight. To 1 L of the above solution, an anti-HBs rabbit antibody (purified product, buffer: 0.036 MPBS) (protein concentration: 1.0 mg / m2)
L, specific antibody titer: 5300 IU / mL (measured with Mediace HBs antibody (manufactured by Sekisui Chemical Co., Ltd.))
L was added to prepare a first neutralizing reagent. [Table 1] (Comparative Example 1) A first reagent for normal measurement was prepared as follows, and the first reagent for neutralization in Example 1 was replaced with the first reagent for confirmation test described in 1) to (2) below. The procedure was performed in the same manner as in Example 1 except that the test was performed using one reagent. The results are shown in Table 2. 1) Preparation of First Reagent (Buffer Solution) (1) Preparation of First Reagent for Normal Measurement PEG was added to 0.05 M PBS containing 1% by weight of BSA.
Was dissolved to a concentration of 1.0% by weight to prepare a first reagent for normal measurement. (2) Preparation of First Reagent for Confirmation Test PEG was dissolved in a Na-HCl borate buffer (pH 9.15) containing 1% by weight of BSA to a concentration of 1.0% by weight, and the confirmation test was performed. A first reagent was prepared. Comparative Example 2 A first reagent for normal measurement was prepared as follows, and the first reagent for neutralization of Example 1 was replaced with the first reagent for neutralization test of 1)-(2) below. The procedure was performed in the same manner as in Example 1 except that the test was performed using one reagent. The results are shown in Table 2. 1) Preparation of First Reagent (Buffer) (1) Preparation of First Reagent for Normal Measurement PEG was added to 0.05M PBS containing 1% by weight of BSA.
Was dissolved to a concentration of 1.0% by weight to prepare a first reagent for normal measurement. (2) Preparation of first reagent for confirmation test In a Na-HCl borate buffer (pH 9.15) containing 1% by weight of BSA, NaCl was adjusted to a concentration of 0.5M, and PEG was added to 1.0%. By dissolving to a concentration of 1% by weight, a first reagent for confirmation test was prepared. [Table 2] In Examples 1 and 2, all five HBs antigen-positive sera showed a value of 8 IU / mL or more in a normal test, and the neutralization rate exceeded 50%. On the other hand, the false positive serum exceeded 8 IU / mL in the normal test in all five samples, but was determined to be negative because the neutralization rate was less than 50%. In Comparative Examples 1 and 2, all five HBs antigen-positive sera showed 8 IU / mL or more in a normal test, and the neutralization rate exceeded 50%, so that the samples were determined to be positive. However, as for the false positive sera, all five samples exceeded 8 IU / mL in the normal test, and four of the five samples also had a neutralization rate of 50% or more, and thus were determined to be positive. Since the present invention has the above-mentioned structure, it is possible to check whether the antigen and / or the antibody has been consumed without the trouble of transferring the sample to another container, which is very simple. A neutralization test of the antigen-antibody reaction can be performed.
Claims (1)
いて、担持された抗原又は抗体に対応する抗体又は抗原
を測定する抗原抗体反応の判定方法であって、前記測定
のための試薬構成は、不溶性担体の懸濁液及び緩衝液か
らなる2液以上の試薬を用い、測定時にはこれらの試薬
が混合されるものであり、前記測定は2度行うものであ
り、第1回目の検体測定時に反応が起こった検体に対し
て、試薬構成中の測定に供する緩衝液を、不溶性担体に
担持したものと同じ抗体又は抗原を含む緩衝液と入れ換
えたのちに第2回目の測定をし、最初の反応に対する、
前記緩衝液での反応の減少度合を測定することにより特
異的反応であるか非特異的反応であるかを判定すること
を特徴とする抗原抗体反応の判定方法。Claims: 1. A method for determining an antigen-antibody reaction in which an insoluble carrier carrying an antigen or an antibody is used to measure an antibody or an antigen corresponding to the carried antigen or the antibody, the method comprising: The reagent configuration for the use of two or more reagents consisting of a suspension of an insoluble carrier and a buffer, these reagents are mixed at the time of measurement, the measurement is performed twice, For a sample in which a reaction has occurred at the time of the first sample measurement, the buffer used for measurement in the reagent composition is replaced with a buffer containing the same antibody or antigen as that supported on the insoluble carrier, and then the second sample is used. Take a measurement and respond to the first reaction
A method for determining an antigen-antibody reaction, comprising determining whether the reaction is a specific reaction or a non-specific reaction by measuring the degree of decrease in the reaction in the buffer solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001181922A JP3692055B2 (en) | 2001-06-15 | 2001-06-15 | Determination method of antigen-antibody reaction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001181922A JP3692055B2 (en) | 2001-06-15 | 2001-06-15 | Determination method of antigen-antibody reaction |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003004741A true JP2003004741A (en) | 2003-01-08 |
JP3692055B2 JP3692055B2 (en) | 2005-09-07 |
Family
ID=19022116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001181922A Expired - Fee Related JP3692055B2 (en) | 2001-06-15 | 2001-06-15 | Determination method of antigen-antibody reaction |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3692055B2 (en) |
-
2001
- 2001-06-15 JP JP2001181922A patent/JP3692055B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP3692055B2 (en) | 2005-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4315907A (en) | Combined heterogeneous specific binding assay | |
JPH11337551A (en) | Non-specific reaction suppression agent, immunity measuring reagent, and immunity measuring method | |
JPH0616044B2 (en) | Immunological latex agglutination method | |
JP2682697B2 (en) | Immunoassay reagents and immunoassays | |
CA2520631C (en) | Turbidimetric immunoassay for lipoprotein(a) and reagent therefor | |
CA2088404C (en) | Method for the determination of antigens or antibodies in the presence of an immune complex | |
JPH026023B2 (en) | ||
JP3692055B2 (en) | Determination method of antigen-antibody reaction | |
EP0333801B1 (en) | Test strip for diagnosis by multi-immunoassay system | |
JPH0712818A (en) | Immunological detection | |
JP3692056B2 (en) | Determination method of antigen-antibody reaction | |
JP3618797B2 (en) | Immunoassay | |
JP2004117068A (en) | Immunoassay reagent and immunoassay method | |
JP3644704B2 (en) | Immunoassay | |
JPH09304386A (en) | Manufacture of immunity diagnostic drug and immunity diagnostic drug obtained | |
JP3968287B2 (en) | Immunoassay method | |
JPH11248703A (en) | Immunological method for measuring free hapten | |
JP3598701B2 (en) | Immunochemical assay using an insoluble carrier | |
JP2003004740A (en) | Method for judging antigen-antibody reaction | |
JPH0552846A (en) | Immune measurement method | |
JPH11337550A (en) | Immunity measurement reagent and immunity measuring method | |
JP2002181822A (en) | Immunoassay reagent and immunoassay method | |
JPH09292396A (en) | Agglutination immunoassay | |
JP2000292424A (en) | Immunoassay method | |
JPH10311830A (en) | Immunoassay reagent and immunoassay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050512 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050525 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050617 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090624 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100624 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100624 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110624 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110624 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120624 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120624 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130624 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |